Physician profile
Stephen V Tang
NPI 1578673190
$1,538.64
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $65.84 · 2021: $387 · 2022: $214 · 2023: $393 · 2024: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $345 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $344.73 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $398.68 | 2019-2024 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $230.42 | 2023-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $181.97 | 2019-2022 | |
| Amgen INC. | $179.62 | 2020-2023 | Otezla |
| Leo Pharma INC. | $164.77 | 2019-2020 | |
| Biofrontera INC. | $107.72 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Celgene Corporation | $102.00 | 2019 | |
| Pfizer INC. | $64.05 | 2019-2023 | |
| Krystal Biotech INC | $46.87 | 2023-2024 | Vyjuvek |
| E.R. Squibb & Sons, L.L.C. | $24.82 | 2023 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $19.23 | 2023 | |
| Sebela Pharmaceuticals INC. | $18.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.